Company Overview
ESTRELLA IMMUNOPHARMA, INC.
ESLARevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
-13M
2025 FY
Shares Outstanding
37M
2025 FY
EPS
-0.35USD
2025 FY
Company Information
SIC Code
2836
CIK Code
1844417
Exchange
Nasdaq
Location
US